Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 5/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10033808 | 0.88 | PYCR1 (0.55) | PYCR1ACHEUTS2RHDAC1 | |
| SCHEMBL10033810 | 0.78 | PYCR1 (0.68) | PYCR1ACHE | |
| SCHEMBL10033800 | 0.75 | RAB9A (0.53) | PYCR1CTSL | |
| SCHEMBL10033804 | 0.74 | PYCR1 (0.45) | PYCR1ACHEHDAC1 | |
| SCHEMBL25554159 | 0.71 | ATM (0.53) | CTSLCTSBCTSS | |
| SCHEMBL2159283 | 0.69 | HPGD (0.61) | — | |
| SCHEMBL25554180 | 0.69 | POLB (0.56) | CTSBUTS2R | |
| SCHEMBL12849869 | 0.68 | RAB9A (0.54) | — | |
| SCHEMBL10143994 | 0.68 | RAB9A (0.54) | — | |
| SCHEMBL10033802 | 0.67 | PTPN1 (0.68) | PYCR1CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124802-B2 | e.g. N-methyl-N-propargyl-4-hydroxybenzyl amine; monoamine oxidase inhibitors; are mediated via a peripheral (i.e., non-CNS) mechanism; antidiabetic agent, metabolic disordes, obesity, insulin resistance | JENRIN DISCOVERY, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124802-B2 | e.g. N-methyl-N-propargyl-4-hydroxybenzyl amine; monoamine oxidase inhibitors; are mediated via a peripheral (i.e., non-CNS) mechanism; antidiabetic agent, metabolic disordes, obesity, insulin resistance | JENRIN DISCOVERY, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| WO-2008092091-A2 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20080182824-A1 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182824-A1 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182824-A1 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | MAOA, MAOB, PNMT | PYCR1 975/4885ACHE 121/4885CTSL 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.